LENZ — Lenz Therapeutics Income Statement
0.000.00%
- $441.49m
- $228.21m
- 35
- 20
- 89
- 45
Annual income statement for Lenz Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.029 | 13.5 | 60.4 | 106 | 135 |
Operating Profit | -0.029 | -13.5 | -60.4 | -106 | -135 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.109 | -68.4 | -70.8 | -101 | -125 |
Net Income After Taxes | -0.109 | -68.4 | -70.8 | -101 | -125 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.109 | -68.4 | -70.8 | -101 | -125 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.109 | -68.4 | -70.8 | -101 | -125 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.013 | -8.24 | -17.1 | -12.9 | -7.67 |
Dividends per Share |